Pörssitiedote25.6.2025 klo 15.00Delisting of the shares of Scandion Oncology - last day of trading July 11, 2025
Pörssitiedote25.6.2025 klo 12.00Scandion Oncology has applied for delisting of the company's shares from Nasdaq First North Growth Market
Pörssitiedote26.2.2025 klo 17.35Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report
Pörssitiedote26.2.2025 klo 17.30Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting
Pörssitiedote13.1.2025 klo 6.00Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer
Pörssitiedote20.11.2024 klo 16.30Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million
Pörssitiedote14.11.2024 klo 7.30Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024
Lehdistötiedote5.11.2024 klo 16.00Invitation to Scandion Oncology webcast and conference call November 11, 2024
Pörssitiedote4.11.2024 klo 7.30Scandion Oncology announces the start of the exercise period for warrants of series TO 2
Pörssitiedote31.10.2024 klo 7.30Correction: Scandion Oncology announces exercise price for warrants of series TO 2
Pörssitiedote30.10.2024 klo 16.00Scandion Oncology announces exercise price for warrants of series TO 2
Lehdistötiedote29.8.2024 klo 10.26Redeye: Scandion Oncology Q2 2024 - Partnership represents best hope